BiotechTube
Bionova Scientific

Bionova Scientific

Fremont, United States· Est.
bionovascientific.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Bionova Scientific is a specialized biologics CDMO offering end-to-end services for therapeutic protein development and manufacturing. The company differentiates itself by combining technical expertise in mammalian cell culture with a flexible, client-centric operational culture. Recent strategic moves, including licensing agreements for cell line development and plasmid DNA production, indicate an expansion of its service portfolio and a focus on advanced therapies. As a private company, it operates in the competitive but growing CDMO market, serving biotech innovators globally.

BiologicsCell Therapy

Technology Platform

Mammalian cell culture platform for therapeutic protein production, enhanced by licensed transposon-based cell line development (ATUM) and partnerships for high-efficiency plasmid DNA manufacturing (Scarab Genomics, Syenex).

Funding History

1
Total raised:$20M
Series A$20M

Opportunities

The growing global demand for biologics and advanced therapies drives sustained need for CDMO services.
Expansion into plasmid DNA production via strategic partnerships positions the company to capture market share in the high-growth cell/gene therapy and mRNA sectors.
A client-first, flexible culture is a key differentiator in attracting small-to-midsize biotech innovators.

Risk Factors

Intense competition from larger, well-capitalized CDMOs and other niche players.
Revenue dependency on a limited number of client projects, exposing the company to program delays or failures.
Significant operational and regulatory execution risk, where any quality or compliance failure could severely damage reputation and client trust.

Competitive Landscape

Bionova competes in the crowded biologics CDMO market against global giants like Lonza and Samsung Biologics, as well as many mid-sized and specialized firms. Its differentiation strategy is twofold: leveraging specific technology licenses (e.g., ATUM's transposon system) for technical edge, and competing on service quality and client partnership agility rather than scale alone. The expansion into plasmid DNA also brings it into competition with dedicated nucleic acid CDMOs.

More companies in Diagnostics & Precision Medicine →More companies in United States →